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Somatic mutation driven codon 
transition bias in human cancer
Hyeonju Son, Hyundeok Kang, Hyun Seok Kim & Sangwoo Kim  
Accumulation of DNA mutations alters amino acid sequence in the key domains of oncoproteins, 
leading to cellular malignant transformation. Due to redundancy of the genetic code, the same 
amino acid alteration can be achieved by multiple distinct genetic mutations, which are considered 
functionally identical and not actively distinguished in the current cancer genome research. For the first 
time, we analyzed the distribution of codon level transitions acquired by somatic mutations in human 
cancers. By analyzing the ~2.5 million nonsynonymous somatic single nucleotide variations (SNVs) 
found in the COSMIC database, we found 41 recurrent amino acid alterations whose DNA changes are 
significantly biased toward a specific codon transition. Additional analyses partially identified functional 
discrepancies between the favored and avoided codon transitions in terms of mutational process, codon 
usage, alternative splicing, and mRNA stability.
Cancer is a genetic disease caused by a single or a few catastrophic somatic mutations that are responsible for 
cellular transformation, with accompanying many passenger mutations1. Many of the identified causal genetic 
changes are a substitution of one base pair in DNA (single nucleotide variation, SNV) that alters an amino acid 
in the corresponding codon (nonsynonymous change). The mutant protein, in turn, may initiate the cascades of 
downstream signaling (e.g., cell proliferation and inhibition of apoptosis) and eventually transforms the cellular 
phenotype from normal to malignant. In this context, the semantic basis of the entire event is the change of amino 
acids, not nucleotides, because different nonsynonymous SNVs are translated to the identical protein level alter-
ation, thereby leading to the same functional impact. With the additional difficulty in locating the exact genomic 
coordinates under the continuing updates of the human reference genome, cancer-associated variants are usually 
represented in terms of the amino acid alteration.
Nonetheless, the redundancy of the genetic code not only causes the amino acid changes but also, along with 
its observational frequency, codon usage can have other functional effects beyond altering translation efficiency2. 
So far, many studies have shown that multiple synonym codons (a set of codons that are translated into the same 
amino acid) have different efficiency regarding the translation process on the ribosome including the speed of 
translation and folding accuracy3. Thus, the use of one codon, instead of the others, may offer a slight advan-
tage or disadvantage over other competitors for a limited resource, especially in some model organisms4–7. One 
working hypothesis is that when mutations are accumulated for a long period, entities may have a significant 
fitness advantage over others, which can results in a deviation among synonym codons8–10. Conversely, numer-
ical representation of this deviation, such as relative synonymous codon usage (RSCU)11 enables researchers to 
infer whether there has been a codon level selection. (see Supplementary Table S1 for the RSCU of human cells) 
Even without identifying the exact molecular process, it is known that the synonym codon usage bias (CUB) is 
common in many species12.
Just as the model organisms and systems for CUB analysis, the tumor environment can be seen as a micro-
cosm of an ecosystem under rapid natural selection13,14 because it satisfies the essential prerequisites of evolution: 
First, genetic variation occurs with an increased frequency due to the uncontrolled proliferation and the com-
promised DNA integrity. Second, cells with different genetic traits (e.g., growth factors or cell cycle regulators) 
acquire different proliferation and death rates10,15. Third, the acquired mutant genotypes are efficiently inherited 
by descendants via clonal expansion. Moreover, cancer cells are usually under harsh environmental pressure such 
as hypoxia16, glucose starvation17, or even physical forces18 to expedite the evolutionary process. This analogy 
leads us to an intriguing question regarding the CUB in cancer cells: is there a favored codon used in cancer 
mutations? Somatic mutations are believed to occur in mostly random manner across the genome; therefore, a 
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biased frequency among mutant synonym codons can be a putative sign for the codon level selection in cancer 
cells along with the conventionally considered external factors such as environmental effects and drug treatment.
Here, we extend previously known CUB to explore the above problem. Instead of measuring the usage of all 
codons, we interrogated whether there is any statistical deviation among synonym codon changes that encode 
the same amino acid alteration, defined as a synonym codon transition bias (CTB). One representative example 
is the methionine-to-isoleucine alteration (Fig. 1a), which is encoded by three different nonsynonymous somatic 
point mutations in the sense strand: MetATG to IleATT (G > T), IleATC (G > C), and IleATA (G > A). A null hypothesis 
is that the three transitions are equally functional and happen in a balanced way due to the randomness of the 
mutations; practically, the nucleotide level mutation frequencies (e.g., transition-to-transversion ratio) must be 
considered (see Methods). On the contrary, severe deviations from the expectation may indicate the presence of 
additional effects at various steps within the Central Dogma. We searched for global and local (specific to a gene 
or a locus) CTBs in a large database of cancer somatic mutations19 and found 41 significantly biased transitions, 
most of which are located in well-known cancer-driver genes (oncogenes and tumor suppressor genes) with a 
sufficient number of recurrences. Multiple computational analyses were conducted to find a possible relation of 
the bias to post-transcriptional efficiency (e.g., RNA secondary structure, translation speed) of the genes with the 
mutant codons.
Overall, the extension and application of codon usage analysis to cancer somatic mutations revealed previ-
ously neglected events that can hardly occur by chance. We anticipate that the reported cancer mutations may 
hold clues to an unexplored mechanism of cancer cell regulation.
Materials and Methods
Basic definitions. We define A as a set of letters that denote 20 standard amino acids (e.g., “Phe,” “Leu,” and 
“Gly”) and one special action for translation termination (“Stop”); we regard the “Stop” letter as an amino acid for 
convenience of description. Nonsynonymous somatic point mutation m alters amino acids from X to Y (X, 
Y ∈ A), which we denoted as ⟶X Ym  (e.g., →>Met IleG T ). We also define C as a set of 64 three-letter codons. A sub-
set of codons CX is the set of codons that encode amino acid X. For example, CMet = {ATG} and CIle = {ATA, ATC, 
ATT}. Then, we define a codon transition with respect to the encoded amino acid as:
= → ∈ ∈
>tr C C X Y C C( , ’) , C , C’ , (1)
C C
X Y
’
where X and Y are the amino acids encoded by C and C’, respectively. We further define a close codon transition as 
a codon transition that can be acquired via a single nucleotide variation (SNV):
= =tr C C ctr C C LD C C( , ’) ( , ’), if and only if ( , ’) 1, (2)
where LD(C, C’) is the Levenshtein distance (or edit distance) between codons C and C’. For example, 
 →
>Met IleATG ATT  is a close codon transition, whereas  →
>Met SerATG AGT  is not.
Now, we define a codon-amino acid transition pathset or simply pathset as a set of close codon transitions from 
a codon C to an amino acid Y:
= ∈ctr C C CP C{ ( , ): }, (3)i i YC,Y
where X is an amino acid encoded by C and X ≠ Y. By definition, a pathset is null when no SNV can convert X 
to Y. For other cases, the size of a pathset indicates the number of unique SNVs that result in the same amino 
acid alteration. For example, N(PGTT,Ala) = 1, where the only close codon transition is tr(GTT, GCT). Similarly, 
N(PAGA,Ser) = 2, because the pathset has two different close codon transitions: tr(AGA, AGT) and tr(AGA, AGC). 
In the rest of this study, the main focus is on pathsets of size ≥2. Intuitively, the cases show that a gene and its 
genomic coordinate fix the initial reference codon, and there are multiple SNVs that lead to the same target 
amino acid alteration. We aimed to investigate whether there is a bias among the SNVs in terms of their observed 
frequencies.
Figure 1. The basic concept and overall workflow. (a) An example of a pathset. Codon ATG in a sense strand 
encodes methionine, in which three mutations (G > A, G > T, G > C) lead to the alteration to isoleucine. (b) All 
somatic mutation events reported in the COSMIC database were tested for the possible codon transition bias 
(CTB) in a pathset. Amino acid alterations with a CTB were further analyzed for potential functionality.
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Identification of codon transition bias. Let PC,Y be a pathset with n close codon transitions {ctr(C, Ci): 
1 ≤ i ≤ n}. In a sufficiently large database, we assume that a total of mi events of somatic nonsynonymous SNVs 
for tr(C, Ci) are observed. Then:
∑ ∑= = ∈ =m N ctr C C C NC Pm ({ ( , ): }) ( ),
(4)i
n
i
i
n
i i Y C,Y
where m is the total number of somatic mutations. We want to test whether there is statistical significance of 
deviation from a theoretically expected distribution of the observations into n categories. Hence, a multinomial 
test is applied. For a multinomial test, a vector of the observed numbers of codon transitions m = (m1, m2, …, mn) 
is defined with matching parameter values under the null hypothesis:
pi = pi pi … piH : ( , , , ), (5)0 1 2 n
where πi is the prior probability of observing ctr(C, Ci) out of all the possible close codon transitions in a pathset, 
and pi∑ = 1in i  (Fig. 1a). The naïve assignment of πi can be n1/ . Nevertheless, we note that the DNA mutation rate 
is specific to a sequence context: a higher mutation rate of transition (Ti: interchanges within purines or within 
pyrimidines) than transversion (Tv: interchanges between a purine and pyrimidine). Regarding the previously 
reported Ti/Tv ratios 2.0–2.120, we assigned 67.75 and 32.25 to πi which correspond to Ti and Tv, respectively, and 
further normalized them so that pi∑ = 1in i . The exact probability of the observed m under the null hypothesis is 
given by
∏
pi
=
= m
mPr( ) m!
! (6)i
n
i
m
i
0
1
i
and the significance probability for the test is calculated as
∑=
≤
ysigPr( ) Pr( )
(7)y y m:Pr( ) Pr( )0
P-values were calculated using the “dmultinom” function in R, and next they were corrected by the Bonferroni 
correction method. Pathsets whose corrected p-values are under 0.05 were assumed to have a synonym CTB.
Analysis of somatic mutations in human cancer. The overall workflow is shown in Fig. 1b. In total, 
11,611,692 somatic mutation events (2,552,891 unique mutations) were downloaded from the COSMIC database, 
version 75 (2015-NOV-24). Among them, 2,581,031 events (1,670,510 unique mutations) were nonsynonymous 
point mutations. Mutation events that belong to the same codon transition (codon C to amino acid Y in a gene) 
were grouped and were assigned to the same pathset PC,Y. The reading frame was determined by the annotated 
transcript information in the COSMIC database (“Accession Number”). When two or more events in the same 
gene are annotated with different transcripts, the reading frame was calculated using the Ensembl database to 
determine whether both are located in the same codon. In total, 307,748 mutation events (219,607 unique muta-
tions) were mapped to codon transitions that belong to pathsets of size ≥2.
Statistical tests (see Methods above) identified 265 pathsets from 32 genes with a significant CTB. The 265 
cases were further inspected for possible artefacts in mutation calling. The most important artefact is the erro-
neous somatic mutation call in the original studies that contributed to the COSMIC database. First, we filtered 
out 18 cases that were disqualified by a reference version error. We next searched for false somatic mutations. We 
noted that germline variants are frequently mislabeled as somatic mutations, where sequencing quality in the 
control sample (e.g., matching blood, saliva, or tissue near a tumor) is compromised; in this case, the germline 
variants look like tumor-only (somatic) mutations. Moreover, such false somatic mutations are likely to have a 
CTB because the source of the mutation is actually common alternative alleles (SNPs). To identify these cases, we 
added two filtering criteria: i) the genomic position of the pathsets is not reported to be an SNP site (no dbSNP 
ID) and ii) if it is a known SNP site, then the allele frequency in the population is less than 0.01. By applying these 
criteria, we filtered out 206 additional cases and were left with only 41 remaining high-confidence cases of a CTB.
Functional assessment of biased codon transitions. We attempted to associate cellular functions with 
the identified pathsets with a CTB. The expected functions were subdivided into two major classes. One is the 
external factor that affects the mutational process itself. We used mutational signature analysis21 to identify the 
causes of mutations, which convert nucleotides more frequently in specific sequence contexts (e.g., tobacco smok-
ing is associated with C > A single and CC > AA dinucleotide mutations). The other explanation of the CTB is 
possible alteration of transcription and translation efficiency. Therefore, we calculated three known measures for 
each pathset (global codon usage, a splicing effect, and mRNA stability), which we used to test whether there is a 
major discrepancy among the synonym codon transitions.
Mutational signature analysis. For this analysis, we extracted 3-bp sequences around the mutation locus 
(1 bp upstream and 1 bp downstream). If possible, the extracted sequence was matched to one of the previously 
reported 30 types of mutational signatures22. We then investigated the organ-specific occurrence of the mutations 
to confirm the assigned mutational signature. For example, if a major codon transition corresponds to the tobacco 
smoking signature and is specifically observed in lung cancer, CTB is well explained by the presence of a mutagen.
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Functional effect analysis. For the other pathsets, which are not sufficiently explained by the mutational signa-
ture, functional assessment was conducted. First, we tested whether the codons that are produced by the major 
transition are more frequently used globally. To test the relative codon usage preference among the codons that 
encode a same amino acid, we used the relative synonymous codon usage (RSCU) defined by Sharp et al.11. 
Briefly, RSCU is calculated by global codon frequency of a specific codon divided by arithmetic mean of global 
codon frequency of synonym codons. The global codon frequency in a human reference genome was downloaded 
from the Codon Usage Database (http://www.kazusa.or.jp/codon/). Using the RSCU values, a difference in RSCU 
between the major and the minor codon (∆RSCU) is defined as:
∆ = −R RRSCU , (8)1 2
where Rn is the RSCU of a codon that is the nth most frequently observed in a pathset. For example, two close 
codon transitions tr(AGA, AGT) and tr(AGA, AGC) in the previously discussed pathset PAGA,Ser were observed 10 
and 20 times respectively. By definition, R1 is the RSCU of AGC (=1.44, see Supplementary Table S1), R2 is the 
RSCU of AGT (=0.90), and the ∆RSCU is 0.54 (=1.44–0.90). Positive ∆RSCU implies that the favored codon 
transition generates a more globally preferred codon.
Second, we predicted the effect of somatic mutations on alternative splicing to test whether a major codon 
transition is associated with a splice aberration event. For each mutation in a given pathset, MutPred Splice ver-
sion 1.3.2 with default options was used to calculate a probabilistic score for a splicing aberration and was then 
classified into splicing altering variants (SAVs) or splice neutral variants23. The predicted score was revalidated by 
means of another tool: Human Splicing Finder, version 3.0.0 with default options24.
Finally, mRNA stability was analyzed for each transcript produced by the set of mutations in a pathset. We 
used RNAfold version 2.2.4 to predict mRNA secondary structure25. We considered two types of features in 
the mRNA stability analysis: the free energy level of the predicted mRNA and the structural similarity with the 
wild-type mRNA. Among all the possible mRNA secondary structures with respect to a given mRNA sequence, 
the one with the lowest free energy (minimum free energy, MFE) and another with maximum accuracy (max-
imum expected accuracy, MEA) were used to assign free energy. The structural similarity was calculated by 
SimTree26, which outputs a normalized score between 0 to 1 (1 means that the two structures are identical). The 
score was further transformed to percentage similarity by multiplying by 100. Consequently, a mutation—that 
forms an altered mRNA transcript whose secondary structure has a lower free energy and is more similar to the 
structure of wild-type mRNA—is considered more stable.
Results
Synonym codon transitions in human cancer. We first enumerated the possible mutation-driven codon 
transitions, in which two or more different nucleotide changes lead to the same amino acid alternation (pathsets, 
see Methods for a formal definition). We found 42 pathsets, 37 of which are pathsets of size 2 (Fig. 2a), and five 
are of size 3 (Fig. 2b). The 42 pathsets consist of 25 unique amino acid alterations, out of all possible 420 cases 
(21P2, the number of ordered pairs from 20 amino acids plus 1 stop codon). Therefore, formation of a pathset is a 
relatively rare event (5.95%). We found that most of the codon transitions are caused by the mutation at the third 
position of the codon. Accordingly, the codon transitions in a pathset tend to have mutations at the same codon 
position.
We next analyzed how the reported somatic mutation events are distributed among the 42 pathsets (Fig. 2c). 
In total, 307,748 somatic mutation events (219,607 unique somatic mutations) were mapped to the 42 pathsets 
(see Methods). The most frequently observed pathset was PATG,Ile, which is encoded by three codon transitions: 
tr(ATG, ATA), tr(ATG, ATT), and tr(ATG, ATC) (as shown in Fig. 1a). On the contrary, pathsets that alter the 
stop codon (PTAA,Tyr, PTAG,Tyr, PTGA,Arg, and PTGA,Cys) were rarely observed, probably due to the higher functional 
impact. Nonetheless, stop causing events (PTAC,STOP, PTAT,STOP, PTCA,STOP, PTGG,STOP, and PTTA,STOP) were much more 
frequently observed than stop loss events were. Although there is no notable association between the number 
of observed events and the amino acid or codon characteristics, it is expected that a greater number of somatic 
mutations occur in codons with high usage.
The number of observed synonym codon transitions in the 42 pathsets shows that the codon transition is 
naturally biased by the sequence context. For example, pathset PGGG,Arg consists of two synonym codon transi-
tions tr(GGG, AGG) and tr(GGG, CGG), which are encoded by mutations G > A and G > C, respectively. It is well 
known that the G > A mutation (transition) occurs more frequently than G > C (transversion), leading to biased 
observation in the COSMIC database (Fig. 2c). Because the bias from the discrepancy between transition and 
transversion is not our primary concern, the expected number of observations was recalibrated by the transition/
transversion ratio (Ti/Tv ratio, see Methods). We found that the corrected expected numbers (blue diamonds in 
Fig. 2c) successfully explain the unbalanced occurrence among synonym codon transitions.
Identification of codon transition bias. On the basis of the Ti/Tv ratio and adjusted multinomial test (see 
Methods), 265 amino acid alteration events were found to have a significant CTB (see Supplementary Table S2 
for the entire list). The overall distribution of p-values shows that most of the amino acid alterations with possible 
multiple paths have no CTB (Fig. 3a), again confirming the rarity (0.12%). Out of the 265 alterations, 224 were 
filtered out based on our false mutation filtering criteria (see Methods), which distinguished true somatic muta-
tions from germ line mutations using large polymorphism databases27. Finally, 41 amino acid alterations were 
finalized to have CTB (Table 1)
A few representative examples are shown in Fig. 3b. The TP53 p.R249S is a well-known somatic amino acid 
alteration in a tumor suppressor, which has been reported 568 times in the COSMIC database. TP53 p.R249S has 
two synonym codon transitions, tr(AGG, AGC) and tr(AGG, AGT), which are encoded by mutations G > C and 
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G > T, respectively, at the third position of the codon. Moreover, we found that the G > T mutations occurred 
much more frequently than G > C (537 times vs. 31 times, corrected p-value < 10−36). The two mutations are 
both transversions, which does not explain the difference sufficiently. ALK p.F1174L is another frequently 
reported somatic amino acid alteration in an oncogene. Pathset PTTC,Leu has three synonym codon transitions: 
tr(TTC, CTC), tr(TTC, TTA), and tr(TTC, TTG). The most frequent codon transition was tr(TTC, TTA), which 
was caused by transversion C > A at the third position of the codon (108 times vs. 12 and 8 times, corrected 
p-value < 10−34). Likewise, two other examples in JAK2 and another TP53 are shown in Fig. 3b.
We conducted functional classification of the 41 amino acid alterations with a CTB (Fig. 3c,d). Frequent 
recurrence of a mutation in cancer is an important factor determining the pathogenicity of cancer mutation. The 
number of recurrences was at least 8 (2 out 41 cases). In more than a half of all cases (22/41, ~54%), the same 
alterations were observed more than 20 times. There were eight cases with >100 occurrences, convincing a func-
tional relation with cancer (Fig. 3c). The 41 alterations occurred in 32 unique genes, seven and three of which are 
classified as oncogenes and tumor suppressor genes, respectively; the classification was based on the databases by 
Min Zhao et al.28,29. The high prevalence of oncogenes and tumor suppressor genes implies a potential functional 
association with cancer initiation and progression. Because most of oncogenes are pathogenic because of one 
mutant allele, a similar distribution was observed in the haplosufficiency analysis (Fig. 3d).
The analysis of the Ti/Tv ratio also supports functionality of the 41 alterations. Under normal conditions, the 
Ti/Tv ratio is between 2.1 and 2.7 as observed in normal whole genome sequencing and the COSMIC database 
(Fig. 3e, left bar graph). Accordingly, the heatmap of nucleotide changes shows enriched transition mutations 
(Fig. 3e, the second heatmap). On the contrary, the Ti/Tv ratio of the 41 alterations was only 0.13 (11.18/88.82), 
and the corresponding heatmap shows an asymmetrical pattern of preferred nucleotide changes (Fig. 3e, right). 
Therefore, the somatic mutations within the selected 41 cases with a CTB are assumed to have a strong functional 
association with cancer.
Figure 2. The complete list of all possible codon transitions with multiple paths and their distribution in 
COSMIC. (a) Thirty-seven pathsets with two synonym codon transitions. Colors in the target codon denote the 
reported general usage of the codons. (red: codons with high usage, blue: codons with low usage, green: codons 
with the lowest usage). (b) Five pathsets with three synonym codon transitions. (c) Distribution of codon 
transitions of the 42 pathsets based on the 307,748 somatic mutation events in COSMIC. The expected number 
of events for each synonym codon transition is indicated by the blue diamonds.
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Analysis of potential causes and effects of codon transition bias. The molecular basis of an extreme 
CTB is unknown and requires further experiments for elucidation and confirmation. Nonetheless, several in silico 
analyses provide a partial explanation for the cause of a CTB and its potential effects.
First, we conducted mutational signature analysis combined with tissue specificity to determine whether 
a specific mutational process is involved in the favored codon transition. The TP53 p.R249S is one exemplary 
case, in which the mutation signature was useful. We found that the overwhelming occurrence of tr(AGG, AGT) 
(mutation G > T, observed 537 times) over tr(AGG, AGC) (mutation G > C, observed 31 times) was intensified 
in the liver and lungs (Fig. 4a, top). Moreover, a recent population-specific study revealed that hepatocellular 
carcinoma that develops in the absence of liver cirrhosis frequently harbors the TP53 p.R249S mutation caused 
by aflatoxin B130. Aflatoxin B1 is a top-tier carcinogen in the liver and lungs that produces the G > T mutation 
induced by 8-hydroxy-2′-deoxyguanosine31. Thus, the extreme CTB in TP53 p.R249S can be caused by the afla-
toxin B1-induced liver and lung cancer. Another example is PIK3CA p.M1043I, which consists of three synonym 
codon transitions: tr(ATG, ATT), tr(ATG, ATA), and tr(ATG, ATC). The G > T mutation (c.3129G>T) is the most 
frequent codon transition (observed 57 times vs. 38 and 10 times for G > A and G > C, respectively; Fig. 4a, mid-
dle). Nevertheless, we found that the dominance of the G > T mutation was observed only in colorectal cancer, 
whereas the G > A mutation was more frequent in other tissues. One of the known mutational signatures, mis-
match repair deficiency, is represented by C > T (G > A) and C > A (G > T) mutations in cancers with microsat-
ellite instability (MSI)32. It is well known that almost 15% of colorectal cancers have the MSI signature. The G > A 
mutation is also known to be related to aggressive endometrial cancer33,34. A similar pattern was discovered in 
KRAS p.Q61H, whose major codon transition c.183A>C is observed in colorectal and pancreatic cancers (Fig. 4a, 
bottom)
Next, we tested whether the codon transition is biased with usage. Out of the 41 amino acid alterations with a 
CTB, 27 cases (65.9%) were biased toward generation of a high usage codon (Fig. 4b, see Supplementary Table S3 
for the ∆RSCU of them). The distribution of the gap between the codon usage rates of the favored and unfla-
vored codons (∆RSCU, see Methods) identified a few cases with large deviations. Although codon usage does not 
resolve the entire case, the tendency toward higher usage suggests that mRNAs with a more efficient conforma-
tion (e.g., faster translation elongation) would be favored by cancer cells. Particularly, recent studies that reported 
alteration of tRNA expression in tumor cell can provide a basis for interpretation of our findings in terms of 
increased translational efficiency10.
We then determined whether some codon transitions are related to the de novo formation or loss of mRNA 
splicing. As shown by recent studies, mRNA splicing is not only determined by the canonical splicing donor 
Figure 3. Characteristics of the 41 amino acid alterations with a CTB. (a) Distribution of the adjusted p-values. 
(b) Four examples of cases with a significant CTB. (c) The number of recurrences of the 41 alterations with a 
CTB. (d) Functional annotation of 32 genes with a CTB. The numbers of oncogenes and tumor suppressor genes 
are indicated with their haplosufficiency. (e) Comparison of the Ti/Tv ratios and mutation rates between the 
whole COSMIC database and 41 mutations with a CTB.
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and acceptor but also affected by various motifs in introns or exons that regulate activity of the spliceosome: 
spice enhancers and silencers35. We annotated all the somatic mutations involved in the 41 alterations with the 
predicted effect size on splicing (see Fig. 4c and Methods). The predicted scores converged on approximately 
zero, which means that splicing was not additionally disrupted in most of the codon transitions. Nonetheless, we 
found six cases whose scores strongly deviated from the average including TP53 p.S106R and PIK3CA p.N345K 
Gene Type Func. Mut AA Mut CDS Recur. Impct Gene Type Func. Mut AA Mut CDS Recur. Impct
TP53 TSG Rec R249S
AGG > AGT 537 NEU
IFITM3 — — G133R
GGA > CGA 11 NEU
AGG > AGC 31 NEU GGA > AGA 0 NEU
PIK3CA OCG Dom N345K
AAT > AAA 123 PAT
TP53 TSG Rec F134L
TTT > CTT 41 NEU
AAT > AAG 0 PAT TTT > TTA 1 NEU
ALK OCG Dom F1174L
TTC > TTA 102 PAT TTT > TTG 2 NEU
TTC > TTG 8 PAT
KCNJ5 — Dom G151R
GGG > AGG 169 PAT
TTC > CTC 12 PAT GGG > CGG 68 PAT
JAK2 OCG Dom V615L
GTA > TTA 130 NEU
PCLO — — S1057*
TCA > TGA 20 PAT
GTA > CTA 0 NEU TCA > TAA 0 PAT
KRAS OCG Dom Q61H
CAA > CAC 240 PAT
RYBP — — G291R
GGG > CGG 10 NEU
CAA > CAT 95 PAT GGG > AGG 0 NEU
SIRPA — — D95E
GAC > GAG 30 NEU
FGFR2 OCG Dom W290C
TGG > TGC 15 PAT
GAC > GAA 0 NEU TGG > TGT 0 PAT
SLC25A5 — — K296N
AAG > AAC 23 PAT
ESYT1 — — S214R
AGC > AGG 18 NEU
AAG > AAT 0 PAT AGC > AGA 0 NEU
MUC4 OCG — H1309Q
CAC > CAG 28 NEU AGC > CGC 0 NEU
CAC > CAA 0 NEU
KMT2C TSG Rec T316S
ACC > TGC 25 NEU
TP53 TSG Rec S183*
TCA > TGA 51 NEU ACC > AGT 1 NEU
TCA > TAA 13 NEU
MLL3 — — T316S
ACC > TGC 25 NEU
LHX1 OCG — K204N
AAG > AAC 22 NEU ACC > AGT 1 NEU
AAG > AAT 0 NEU
BAT2D1 — — M267I
ATG > ATT 14 NEU
AGAP8 — — Q567H
CAG > CAC 22 NEU ATG > ATC 0 NEU
CAG > CAT 0 NEU ATG > ATA 0 NEU
ZNF429 — — K556N
AAG > AAC 24 NEU
STRA8 — — E212D
GAG > GAC 14 NEU
AAG > AAT 1 NEU GAG > GAT 0 NEU
JPH3 — — V581L
GTG > CTG 21 NEU
APOBR — — E352D
GAG > GAC 14 NEU
GTG > TTG 0 NEU GAG > GAT 0 NEU
NBPF10 — — K31N
AAG > AAC 19 NEU
TP53 TSG Rec E258D
GAA > GAT 36 PAT
AAG > AAT 0 NEU GAA > GAC 3 PAT
TP53 TSG Rec S106R
AGC > AGG 23 NEU
ADAD2 — — K16N
AAG > AAC 13 NEU
AGC > AGA 0 NEU AAG > AAT 0 NEU
AGC > CGC 0 NEU
BNC2 — — S575R
AGT > CGT 16 NEU
PIK3CA OCG Dom M1043I
ATG > ATT 57 PAT AGT > AGA 0 NEU
ATG > ATA 38 PAT AGT > AGG 0 NEU
ATG > ATC 10 PAT
GIGYF2 — — G108R
GGA > CGA 8 PAT
TP53 TSG Rec K132N
AAG > AAC 82 PAT GGA > AGA 0 PAT
AAG > AAT 76 PAT
NPM1 Both Dom G90R
GGG > CGG 8 PAT
FAM75A3 — — E950D
GAG > GAC 18 NEU GGG > AGG 0 PAT
GAG > GAT 0 NEU
TP53 TSG Rec S215R
AGT > AGG 33 NEU
CCDC136 TSG — Q396H
CAG > CAC 18 NEU AGT > CGT 7 NEU
CAG > CAT 0 NEU AGT > AGA 19 NEU
SLC25A5 — — F271L
TTC > CTC 20 NEU
APOBR — — E361D
GAG > GAC 12 NEU
TTC > TTA 0 NEU GAG > GAT 0 NEU
TTC > TTG 0 NEU
ASPM — — K3446N
AAG > AAC 12 NEU
POU2F2 — — S449R
AGC > CGC 14 NEU AAG > AAT 0 NEU
AGC > AGA 0 NEU
AGC > AGG 0 NEU
Table 1. Forty-one mutations with a CTB (arranged by p-values in ascending order). *Abbreviations: Func.: 
Haplosufficiency. Recur.: Recurrence. Impct: FATHMM prediction result. Mut AA: Amino acid mutation. Mut 
CDS: Codon alteration. OCG: Oncogene. TSG: Tumor Suppressor Gene. Both: OCG & TSG. Dom: Dominant. 
Rec: Recessive. NEU: Neutral. PAT: Pathogenic.
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(Table 2). Out of the three possible synonym codon transitions in TP53 p.S106R, only the favored mutation C > G 
was observed (23 times vs. 0 times). The C > G mutations are predicted to generate a new donor site as well as a 
new exonic splice enhancer. The disruption in the structural regulation of TP53 may accelerate the breakdown 
of its function as a tumor suppressor and can be favored by a cancer cell. In contrast, splicing affecting codon 
transition tr(AAT, AAA) is avoided in PIK3CA p.N345K (0 vs. 123 times, Table 2). We believe that the de novo 
generation of a splice acceptor may lead to disruption of the oncogene itself, thereby preventing proliferation of 
Figure 4. Functional assessment results. (a) Distribution by histology and tissues of origin in cases related to 
mutational signatures and tissue specificity. (b) Distribution of the gap between codon usage rates (left) and the 
quantitative status (right). (c) Distribution of predicted effect sizes on splicing. (d) Distribution of differences 
in the MFE (left) and MEA (right) of the codons in the pathset associated with RNA stability. (e) Two extreme 
cases of maximum expected accuracy of free energy of a conformation’s secondary structure (JPH3 p.V581L and 
POU2F2 p.S449R).
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the cells. Although the exact mechanisms should be validated in further studies, the different effects on mRNA 
splicing and their mode of action must be considered with respect to the original function of the genes.
Finally, we analyzed the effects of synonym codon transitions on mRNA stability (Fig. 4d). To measure the sta-
bility, secondary structures of mRNAs were predicted using two options (MFE and maximum expected accuracy: 
MEA, see Methods). For each predicted conformation, free energy was calculated. We first tested whether the free 
energy of the favored mRNA conformation strongly deviates from that of the avoided conformation. We found 
that the gap between the free energies is negligible in most cases (~0 kcal/mol), with only a few outliers including 
JPH3 p.V581L and POU2F2 p.S449R (see Fig. 4d). In addition to the different free energies, the synonym codon 
transitions generated mRNAs of highly different secondary structures (Fig. 4e). The frequently observed struc-
ture of JPH3 p.V581L (c.1741G>C, 21 times vs. 0 times) was predicted to be less stable (higher free energy). In 
addition, the structural similarity with the wild-type JPH3 mRNA was much lower as compared to the avoided 
conformation (69.79% vs. 95.38%). In another case of POU2F2 p.S449R, the favored conformation is less stable 
than the other one, but the similarity to the wild-type structure was much higher (94.50% vs. 79.04%), showing 
that the increased mRNA stability is not always favored among the synonym codon transitions.
Discussion
In all the statistical analyses and further in silico analyses, our study has some limitations. First, the biased 
observed frequency among different codon transitions can be caused by many factors that we did not consider. A 
mutational signature is only a part of clustering methods for identifying somatic mutation patterns. Any distant 
functional elements can affect DNA mutations at a specific site, and this effect can even be transient. There are 
many environmental or other external factors (e.g., carcinogen or virus) that cause a specific type of mutation, 
thereby leading to a biologically irrelevant codon transition bias. For example, tobacco smoking, aflatoxin and 
HPV infection can cause a genuine signature. Due to the limited sample and clinical information in the COSMIC 
database, we could not subgroup patients with different clinical characteristics. Further collection of somatic 
mutations with rich clinical annotation will enable a more accurate analysis of those factors. Second, the com-
putational predictions used in this study are relatively less robust due to the stochastic nature of mRNA splicing 
and structure. Thus, the functional mechanisms of a CTB in a specific gene should be confirmed in a deeper 
experimental study. Sufficient expression data of protein or RNAs in cancer gene would help to validate it. Third, 
integrity of the COSMIC database can compromise the reliability of our entire study. As we already found at the 
filtering step (see Methods), the COSMIC database contains many false somatic mutations that are mislabeled by 
mutation callers. The continuous updates of the database should lead to a more reliable analysis on a larger scale 
in the future.
Conclusions
In this study, multiple sets of mutations that lead to the same amino acid substitution were grouped and ana-
lyzed for a bias in a large-scale database of cancer somatic mutations. We identified 41 recurrent and potentially 
cancer-associated amino acid alterations with a significant CTB. The cause and possible effects of the CTB were 
also studied with respect to a mutational signature, codon usage, splicing effects, and mRNA stability. This is the 
first study to analyze cancer somatic mutations at the codon level, and this approach may uncover previously 
unexplored mechanisms that regulate cancer initiation and maintenance.
Gene Type HaploSufficiency
Amino acid 
Mutation CodonAlteration Recur. MSGS
HSF Predicted Signal
Splice 
site ESS ESE
TP53 TSG Rec S106R
AGC > AGG 23 0.97 O(ND) O O
AGC > AGA 0 0.28 O
AGC > CGC 0 0.22
NPM1 Both Dom G90R
GGG > CGG 8 0.41
GGG > AGG 0 0.71 O(NA) O
PIK3CA OCG Dom N345K
AAT > AAA 123 0.58
AAT > AAG 0 0.89 O(NA) O O
KCNJ5 — Dom G151R
GGG > AGG 169 0.81
GGG > CGG 68 0.70
ESYT1 — — S214R
AGC > AGG 18 0.93 O
AGC > AGA 0 0.82 O O
AGC > CGC 0 N/A O(BD) O
Table 2. Mutation with a CTB predicted to have a splicing effect. *Abbreviations: Recur.: Recurrence. MSGS: 
MutPred Splice General Score. HSF: Human Splice Finder. OCG: Oncogene. TSG: Tumor Suppressor Gene. 
Both: OCG & TSG. ESS: New Exonic Splicing. Silencers (ESS) site. ESE: Exonic Splicing Enhancers (ESE) 
site broken. NA: New Acceptor site. ND: New Donor site. BD: Broken WT Donor site. Dom: Dominant. Rec: 
Recessive.
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